Cargando…

Markers of exacerbation severity in chronic obstructive pulmonary disease

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) can experience 'exacerbations' of their conditions. An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in m...

Descripción completa

Detalles Bibliográficos
Autores principales: Franciosi, Luigi G, Page, Clive P, Celli, Bartolome R, Cazzola, Mario, Walker, Michael J, Danhof, Meindert, Rabe, Klaus F, Pasqua, Oscar E Della
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1481583/
https://www.ncbi.nlm.nih.gov/pubmed/16686949
http://dx.doi.org/10.1186/1465-9921-7-74
_version_ 1782128268940410880
author Franciosi, Luigi G
Page, Clive P
Celli, Bartolome R
Cazzola, Mario
Walker, Michael J
Danhof, Meindert
Rabe, Klaus F
Pasqua, Oscar E Della
author_facet Franciosi, Luigi G
Page, Clive P
Celli, Bartolome R
Cazzola, Mario
Walker, Michael J
Danhof, Meindert
Rabe, Klaus F
Pasqua, Oscar E Della
author_sort Franciosi, Luigi G
collection PubMed
description BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) can experience 'exacerbations' of their conditions. An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management. There is a need for reliable markers that reflect the pathological mechanisms that underlie exacerbation severity and that can be used as a surrogate to assess treatment effects in clinical studies. Little is known as to how existing study variables and suggested markers change in both the stable and exacerbation phases of COPD. In an attempt to find the best surrogates for exacerbations, we have reviewed the literature to identify which of these markers change in a consistent manner with the severity of the exacerbation event. METHODS: We have searched standard databases between 1966 to July 2004 using major keywords and terms. Studies that provided demographics, spirometry, potential markers, and clear eligibility criteria were included in this study. Central tendencies and dispersions for all the variables and markers reported and collected by us were first tabulated according to sample size and ATS/ERS 2004 Exacerbation Severity Levels I to III criteria. Due to the possible similarity of patients in Levels II and III, the data was also redefined into categories of exacerbations, namely out-patient (Level I) and in-patient (Levels II & III combined). For both approaches, we performed a fixed effect meta-analysis on each of the reported variables. RESULTS: We included a total of 268 studies reported between 1979 to July 2004. These studies investigated 142,407 patients with COPD. Arterial carbon dioxide tension and breathing rate were statistically different between all levels of exacerbation severity and between in out- and in-patient settings. Most other measures showed weak relationships with either level or setting, or they had insufficient data to permit meta-analysis. CONCLUSION: Arterial carbon dioxide and breathing rate varied in a consistent manner with exacerbation severity and patient setting. Many other measures showed weak correlations that should be further explored in future longitudinal studies or assessed using suggested mathematical modelling techniques.
format Text
id pubmed-1481583
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-14815832006-06-22 Markers of exacerbation severity in chronic obstructive pulmonary disease Franciosi, Luigi G Page, Clive P Celli, Bartolome R Cazzola, Mario Walker, Michael J Danhof, Meindert Rabe, Klaus F Pasqua, Oscar E Della Respir Res Research BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) can experience 'exacerbations' of their conditions. An exacerbation is an event defined in terms of subjective descriptors or symptoms, namely dyspnoea, cough and sputum that worsen sufficiently to warrant a change in medical management. There is a need for reliable markers that reflect the pathological mechanisms that underlie exacerbation severity and that can be used as a surrogate to assess treatment effects in clinical studies. Little is known as to how existing study variables and suggested markers change in both the stable and exacerbation phases of COPD. In an attempt to find the best surrogates for exacerbations, we have reviewed the literature to identify which of these markers change in a consistent manner with the severity of the exacerbation event. METHODS: We have searched standard databases between 1966 to July 2004 using major keywords and terms. Studies that provided demographics, spirometry, potential markers, and clear eligibility criteria were included in this study. Central tendencies and dispersions for all the variables and markers reported and collected by us were first tabulated according to sample size and ATS/ERS 2004 Exacerbation Severity Levels I to III criteria. Due to the possible similarity of patients in Levels II and III, the data was also redefined into categories of exacerbations, namely out-patient (Level I) and in-patient (Levels II & III combined). For both approaches, we performed a fixed effect meta-analysis on each of the reported variables. RESULTS: We included a total of 268 studies reported between 1979 to July 2004. These studies investigated 142,407 patients with COPD. Arterial carbon dioxide tension and breathing rate were statistically different between all levels of exacerbation severity and between in out- and in-patient settings. Most other measures showed weak relationships with either level or setting, or they had insufficient data to permit meta-analysis. CONCLUSION: Arterial carbon dioxide and breathing rate varied in a consistent manner with exacerbation severity and patient setting. Many other measures showed weak correlations that should be further explored in future longitudinal studies or assessed using suggested mathematical modelling techniques. BioMed Central 2006 2006-05-10 /pmc/articles/PMC1481583/ /pubmed/16686949 http://dx.doi.org/10.1186/1465-9921-7-74 Text en Copyright © 2006 Franciosi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Franciosi, Luigi G
Page, Clive P
Celli, Bartolome R
Cazzola, Mario
Walker, Michael J
Danhof, Meindert
Rabe, Klaus F
Pasqua, Oscar E Della
Markers of exacerbation severity in chronic obstructive pulmonary disease
title Markers of exacerbation severity in chronic obstructive pulmonary disease
title_full Markers of exacerbation severity in chronic obstructive pulmonary disease
title_fullStr Markers of exacerbation severity in chronic obstructive pulmonary disease
title_full_unstemmed Markers of exacerbation severity in chronic obstructive pulmonary disease
title_short Markers of exacerbation severity in chronic obstructive pulmonary disease
title_sort markers of exacerbation severity in chronic obstructive pulmonary disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1481583/
https://www.ncbi.nlm.nih.gov/pubmed/16686949
http://dx.doi.org/10.1186/1465-9921-7-74
work_keys_str_mv AT franciosiluigig markersofexacerbationseverityinchronicobstructivepulmonarydisease
AT pageclivep markersofexacerbationseverityinchronicobstructivepulmonarydisease
AT cellibartolomer markersofexacerbationseverityinchronicobstructivepulmonarydisease
AT cazzolamario markersofexacerbationseverityinchronicobstructivepulmonarydisease
AT walkermichaelj markersofexacerbationseverityinchronicobstructivepulmonarydisease
AT danhofmeindert markersofexacerbationseverityinchronicobstructivepulmonarydisease
AT rabeklausf markersofexacerbationseverityinchronicobstructivepulmonarydisease
AT pasquaoscaredella markersofexacerbationseverityinchronicobstructivepulmonarydisease